- Home
- WIW vs XNCR Comparison
WIW vs XNCR Comparison
Compare WIW & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIW
- XNCR
- Stock Information
- Founded
- WIW 2004
- XNCR 1997
- Country
- WIW United States
- XNCR United States
- Employees
- WIW N/A
- XNCR N/A
- Industry
- WIW Finance Companies
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- WIW Finance
- XNCR Health Care
- Exchange
- WIW Nasdaq
- XNCR Nasdaq
- Market Cap
- WIW 540.9M
- XNCR 547.8M
- IPO Year
- WIW N/A
- XNCR 2013
- Fundamental
- Price
- WIW $8.91
- XNCR $8.41
- Analyst Decision
- WIW
- XNCR Buy
- Analyst Count
- WIW 0
- XNCR 9
- Target Price
- WIW N/A
- XNCR $25.00
- AVG Volume (30 Days)
- WIW 229.9K
- XNCR 718.6K
- Earning Date
- WIW 01-01-0001
- XNCR 08-06-2025
- Dividend Yield
- WIW 11.14%
- XNCR N/A
- EPS Growth
- WIW N/A
- XNCR N/A
- EPS
- WIW N/A
- XNCR N/A
- Revenue
- WIW N/A
- XNCR $146,929,000.00
- Revenue This Year
- WIW N/A
- XNCR N/A
- Revenue Next Year
- WIW N/A
- XNCR $28.84
- P/E Ratio
- WIW N/A
- XNCR N/A
- Revenue Growth
- WIW N/A
- XNCR N/A
- 52 Week Low
- WIW $8.01
- XNCR $6.92
- 52 Week High
- WIW $9.37
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- WIW 63.57
- XNCR 55.89
- Support Level
- WIW $8.74
- XNCR $7.13
- Resistance Level
- WIW $8.87
- XNCR $7.99
- Average True Range (ATR)
- WIW 0.06
- XNCR 0.53
- MACD
- WIW 0.01
- XNCR 0.06
- Stochastic Oscillator
- WIW 98.82
- XNCR 94.90
About WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.